NCT03420768

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study of experimental medication BMS-986263 in adult patients with advanced hepatic fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after the patient is cured of hepatitis C (an infection caused by a virus that attacks the liver and leads to inflammation).

Conditions

• Hepatic Cirrhosis
• Liver Fibrosis

Interventions

Type	Name	Description
DRUG	BMS-986263	Administered by intravenous (IV) infusion
OTHER	Placebo	Administered by intravenous (IV) infusion

Timeline

• Start date: 2018-02-14
• Primary completion: 2018-12-10
• Completion: 2019-05-28
• First posted: 2018-02-05
• Last updated: 2022-02-04
• Results posted: 2022-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study